| Prev Close: | 46.89 |
|---|---|
| Open: | N/A |
| Bid: | 46.45 x 600 |
| Ask: | 46.87 x 600 |
| 1y Target Est: | 46.25 |
| Beta: | N/A |
| Next Earnings Date: | 23-Oct-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 30.64 - 49.57 |
| Volume: | 0 |
| Avg Vol (3m): | 7,061,830 |
| Market Cap: | 77.77B |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Pharmaceuticals companiesAP(Tue, Oct 1)
- Roche Pulls Ahead in Immunotherapy Raceat Motley Fool(Tue, Oct 1)
- Healthcare Stocks Up as Obamacare Takes HoldWyatt Investment Research(Tue, Oct 1)
- [$$] Merck Revamp Should Lift Stockat Barrons.com(Tue, Oct 1)
- Merck rises after announcing major restructuringat theflyonthewall.com(Tue, Oct 1)
- Midday Glance: Pharmaceuticals companiesAP(Tue, Oct 1)
- CORRECTING and REPLACING Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual MeetingBusiness Wire(Tue, Oct 1)
- Bristol-Myers Squibb to Announce Results for Third Quarter 2013 on October 23Business Wire(Tue, Oct 1)
- Early Glance: Pharmaceuticals companiesAP(Tue, Oct 1)
- Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Momo Momentum Stockat TheStreet(Tue, Oct 1)
- 5 Stocks Going Ex-Dividend Tomorrow: BDN, GNTX, RGLD, MDT, BMYat TheStreet(Tue, Oct 1)
- 3 Cancer Investing Opportunitiesat Seeking Alpha(Tue, Oct 1)
- Is Achillion a Bad News Buy Post-Bloodbath?at Motley Fool(Tue, Oct 1)
- Roche to show investors strength in and beyond cancer drugsReuters(Tue, Oct 1)
- Will a New Diabetes Treatment Fuel This Company's Top Line Growth?at Motley Fool(Mon, Sep 30)
Press Releases
- CORRECTING and REPLACING Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual MeetingBusiness Wire(Tue, Oct 1)
- Bristol-Myers Squibb to Announce Results for Third Quarter 2013 on October 23Business Wire(Tue, Oct 1)
- Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy® (ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable MelanomaBusiness Wire(Fri, Sep 27)
Reports
- BMY: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Oct 2)
- ValuEngine Industry Report for Large CAP PharmaValuEngine, Inc.(Oct 2)
- Trading Report for (BMY). A detailed report, including free correlated market...Stock Traders Daily(Oct 2)